Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550769 | 0.93 | HDAC2 (0.53) | HDAC2HDAC1ADORA2A | |
| SCHEMBL3557105 | 0.92 | HDAC1 (0.55) | HDAC2HDAC1ADORA2A | |
| SCHEMBL3556383 | 0.91 | HDAC1 (0.51) | HDAC2HDAC1ADORA2A | |
| SCHEMBL4760599 | 0.89 | HDAC1 (0.55) | HDAC2HDAC1ADORA2A | |
| SCHEMBL8420480 | 0.87 | HDAC1 (0.56) | HDAC2HDAC1ADORA2A | |
| SCHEMBL3555346 | 0.87 | HDAC1 (0.55) | HDAC2HDAC1ADORA2A | |
| SCHEMBL3549494 | 0.87 | MAOA (0.48) | HDAC2HDAC1ADORA2A | |
| SCHEMBL3557076 | 0.86 | HDAC1 (0.55) | HDAC2HDAC1ADORA2A | |
| SCHEMBL3554525 | 0.85 | HDAC2 (0.58) | HDAC2HDAC1ADORA2A | |
| SCHEMBL16083176 | 0.85 | HDAC1 (0.55) | HDAC2HDAC1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | claimed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885ADORA2A 4302/4885 |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885ADORA2A 4302/4885 |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885ADORA2A 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.